中国再生医学(08158)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08158 中国再生医学

休市中 06-18 15:13:43

0.320

+0.005

+1.59%

最高0.325	最低0.280	成交量3.76万
今开0.320	昨收0.315	日振幅14.29%
总市值9,728万	流通市值9,728万	总股本3.04亿
成交额1.16万	换手率0.01%	流通股本3.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08158","market":"HK","secType":"STK","nameCN":"中国再生医学","latestPrice":0.32,"timestamp":1781766823008,"preClose":0.315,"halted":0,"volume":37625,"delay":0,"changeRate":0.015873015873015886,"floatShares":304000000,"shares":304000000,"eps":0.0905,"marketStatus":"休市中","change":0.005,"latestTime":"06-18 15:13:43","open":0.32,"high":0.325,"low":0.28,"amount":11631,"amplitude":0.142857,"askPrice":0.32,"askSize":5000,"bidPrice":0.285,"bidSize":40000,"shortable":0,"etf":0,"ttmEps":0.0905,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":7,"adr":0,"listingDate":995385600000,"exchange":"SEHK","adjPreClose":0.315,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":2.0902777603587963,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08158","defaultTab":"news","newsList":[{"id":"1102007519","title":"中国再生医学：2015年新购股权计划获正式采纳，限额达30,425,248份","url":"https://stock-news.laohu8.com/highlight/detail?id=1102007519","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102007519?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:35","pubTimestamp":1781256916,"startTime":"0","endTime":"0","summary":"在截至2015年12月31日的年度内，中国再生医学于当年6月27日正式采纳新购股权计划，适用期限覆盖至2015年年底。根据公告，该计划当年可授出的购股权数目为30,425,248份，另在“服务提供商分项限额”下可另行授出3,042,524份。公司同时指出，此次补充公告所披露的内容并不影响2015年年报中其他已公布的事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学：2015年新购股权计划获正式采纳，限额达30,425,248份","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170335622","title":"中国再生医学5月股份变动月报表：公司股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170335622","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170335622?lang=zh_cn&edition=full","pubTime":"2026-06-03 11:01","pubTimestamp":1780455719,"startTime":"0","endTime":"0","summary":"中国再生医学于2026年6月3日发布2026年5月股份变动月报表。本次月报所披露的报告期为2026年5月1日至5月31日。本月内公司并未进行任何新的股份发行、购回、注销或库藏股变动，股本结构保持稳定。受该期权计划行使所产生的新股及库藏股份本月均未有实际变动，同时公司确认遵守香港联交所《上市规则》及相关法律法规。公告由公司秘书陈乐彤签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114148276","title":"中国再生医学(08158)拟回购最多10%已发行股本","url":"https://stock-news.laohu8.com/highlight/detail?id=1114148276","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114148276?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:06","pubTimestamp":1780398393,"startTime":"0","endTime":"0","summary":"中国再生医学，于香港联交所GEM上市，正计划在2026年6月26日举行股东周年大会上寻求股东授予一般性授权，以回购不超过其已发行股份总数10%的股份。董事会指出，按2026年5月28日已发行的约3.04亿股计算，拟回购上限约为3042.52万股。根据公告，此次回购的资金将来自公司的可分配溢利或发行股份所得等合法来源，并遵循开曼群岛公司法及GEM上市规则。此次回购计划最终实施尚需股东大会批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学(08158)拟回购最多10%已发行股本","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168498276","title":"中国再生医学公布4月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1168498276","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168498276?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:26","pubTimestamp":1777893997,"startTime":"0","endTime":"0","summary":"中国再生医学于2026年5月4日发布2026年4月股份变动月报表。公告显示，公司本月底法定注册股本维持在50亿股，每股面值为0.2港元，注册股本总额为10亿港元，与上月底保持一致。报告期末，公司已发行股份总数为304,252,480股，库存股份数目为零，较上月底均无变化。公司表示，所有本月涉及的证券发行或库藏股相关事务，已获得董事会正式授权并严格遵守联交所《上市规则》和相关法律法规的规定。本次月报由公司秘书陈乐彤签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182948386","title":"中国再生医学(08158)聚焦跨境医疗服务 年度净利同比大增55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182948386","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182948386?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:41","pubTimestamp":1777369274,"startTime":"0","endTime":"0","summary":"2025年度，中国再生医学在跨境医疗需求回升及成本管控等多重举措下，实现收入约72,060,000港元，同比下降约20.48%，但年度溢利约27,530,000港元，相比2024年度的17,750,000港元上升约55%。毛利约41,920,000港元，与收入走势同步同比减少27.29%。展望后续经营，集团将继续围绕跨境医疗、美容与健康服务的协同拓展，结合香港与内地市场的合作机遇，强化核心竞争力并稳步推进资源配置与业务升级。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学(08158)聚焦跨境医疗服务 年度净利同比大增55%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168340591","title":"中国再生医学3月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1168340591","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168340591?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:21","pubTimestamp":1775020874,"startTime":"0","endTime":"0","summary":"2026年4月1日，中国再生医学国际有限公司公布2026年3月股份变动月报表。报告期内，公司已发行及注册股本无变动，股本结构总体保持稳定。公司披露，截至本报告期末，法定注册股本维持为5,000,000,000股，每股面值港币0.2元，合计相当于港币10亿元。公司同时确认公众持股量满足相关上市规则要求。本月报表由公司秘书陈乐彤签署。公司强调将继续严格履行信息披露义务，并确保股本结构及公众持股量符合监管要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622087163","title":"中国再生医学(08158)发布年度业绩 股东应占溢利2752.5万港元 同比增长55.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622087163","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622087163?lang=zh_cn&edition=full","pubTime":"2026-03-28 01:00","pubTimestamp":1774630816,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国再生医学(08158)发布截至2025年12月31日止财政年度全年业绩，集团收益7205.5万港元，同比减少20.48%;股东应占溢利2752.5万港元，同比增长55.05%;每股盈利9.05港仙。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133596390","title":"中国再生医学2025财年净利大增55%，收益与成本结构双向调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1133596390","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133596390?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:17","pubTimestamp":1774613875,"startTime":"0","endTime":"0","summary":"中国再生医学于截至2025年12月31日止年度录得收益7,205.50万元，较上一财年的9,061.70万元下降20.5%，毛利4,191.60万元，毛利率为58.2%。公司拥有人应占年度溢利2,752.50万元，较上一年度的1,775.20万元增长55.0%，每股基本盈利为9.05港仙，上一财年为5.83港仙。溢利增长主要受所得税抵免增加1,233.60万元、行政及其他开支由4,489.20万元降至3,681.50万元、其他收入及其他收益由45.80万元增至1,798.50万元等因素推动。报告期内，经营溢利为1,639.20万元，财务费用120.30万元，除所得税前溢利1,518.90万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162144026","title":"中国再生医学：预计2025财年归母净利润同比增幅不低于28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162144026","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162144026?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:56","pubTimestamp":1774446962,"startTime":"0","endTime":"0","summary":"中国再生医学（08158）3月25日发布正面盈利预告，预计截至2025年12月31日止财年，集团归属于公司股东的净利润将较上一财年增加不少于28%。\\n\\n公司表示，利润增长主要得益于本财年确认过去年度所得税超额拨备所带来的所得税抵免。\\n\\n管理层指出，目前相关数据基于对未经审计综合管理账目的初步评估，最终结果将以2026年3月27日左右发布的经审计年度业绩为准。\\n\\n公司提醒投资者在买卖股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622079071","title":"中国再生医学(08158)发盈喜 预计2025年度股东应占溢利增加不低于28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622079071","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622079071?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:54","pubTimestamp":1774446893,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国再生医学(08158)发布公告，与2024年同期相比，预期集团于截至2025年12月31日止年度将取得公司拥有人应占溢利增加不低于28%。预期公司拥有人应占溢利增加乃主要由于2025财年自过往年度利得税超额拨备确认所得税抵免所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学(08158)发盈喜 预计2025年度股东应占溢利增加不低于28%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08158","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139494047","title":"中国再生医学国际：预计利润增长主要源于2025财年确认所得税抵免","url":"https://stock-news.laohu8.com/highlight/detail?id=1139494047","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139494047?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:53","pubTimestamp":1774446801,"startTime":"0","endTime":"0","summary":"中国再生医学国际（股票代码：08158）近日发布盈利预告，预计公司2025财年利润将实现显著增长。\n此次利润提升主要归因于公司在2025财年确认了一笔可观的所得税抵免收入。该税务优惠将对公司整体财务状况产生积极影响，有助于增强盈利能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617549725","title":"中国再生医学盘中异动 下午盘大幅下挫8.57%报0.320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549725","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617549725?lang=zh_cn&edition=full","pubTime":"2026-03-04 13:37","pubTimestamp":1772602634,"startTime":"0","endTime":"0","summary":"2026年03月04日下午盘13时37分，中国再生医学股票出现波动，股价大幅跳水8.57%。截至发稿，该股报0.320港元/股，成交量1.5万股，换手率0.00%，振幅8.57%。资金方面，该股资金流入0港元，流出3325港元。中国再生医学股票所在的医疗及医学美容服务行业中，整体跌幅为0.33%。其相关个股中，健康之路、固生堂、熙康云医院涨幅较大，振幅较大的相关个股有万嘉集团股权、天元医疗、美中嘉和，振幅分别为21.74%、17.50%、12.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304133714a449c534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304133714a449c534&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190256376","title":"中国再生医学国际（08158）2026年2月股份变动月报：股本维持304,252,480股","url":"https://stock-news.laohu8.com/highlight/detail?id=1190256376","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190256376?lang=zh_cn&edition=full","pubTime":"2026-03-02 15:01","pubTimestamp":1772434913,"startTime":"0","endTime":"0","summary":"中国再生医学国际有限公司于2026年3月2日发布2026年2月股份变动月报。公告显示，截至2月28日，公司法定注册股本仍为50亿股，总面值维持在10亿港元，与上月保持一致。公司截至2月底的已发行股份总数为304,252,480股，库藏股数为零。公告确认公司公众持股量符合相关上市规则要求，股本结构维持稳定。公司同时声明遵守香港联交所《上市规则》及其他适用法律法规，公告由公司秘书陈乐彤签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614073149","title":"中国再生医学股价上涨14.47% 市值涨1915.1万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614073149","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614073149?lang=zh_cn&edition=full","pubTime":"2026-02-26 11:03","pubTimestamp":1772074996,"startTime":"0","endTime":"0","summary":"2026年02月26日早盘11时03分，中国再生医学股票出现波动，股价急速拉升14.47%。资金方面，该股资金流入1.7775万港元，流出6525港元。最近的财报数据显示，该股实现营业收入2,739.10万港元，净利润460.90万港元，每股收益0.0151港元，毛利1,788.20万港元，市盈率7.46倍。中国再生医学股票所在的医疗及医学美容服务行业中，整体跌幅为0.40%。中国再生医学公司简介：本公司为投资控股公司,其附属公司的主要业务为提供医美服务及保健产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226110316954208e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226110316954208e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08158","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612530982","title":"中国再生医学盘中异动 早盘股价大涨9.72%报0.395港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612530982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612530982?lang=zh_cn&edition=full","pubTime":"2026-02-20 10:51","pubTimestamp":1771555872,"startTime":"0","endTime":"0","summary":"2026年02月20日早盘10时51分，中国再生医学股票出现异动，股价大幅上涨9.72%。截至发稿，该股报0.395港元/股，成交量10000股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出3950港元。中国再生医学股票所在的医疗及医学美容服务行业中，整体跌幅为0.35%。其相关个股中，中国再生医学、明基医院、金威医疗涨幅较大，振幅较大的相关个股有康圣环球、美中嘉和、一脉阳光，振幅分别为14.17%、6.70%、6.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220105112a4b51bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220105112a4b51bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08158","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610574981","title":"中国再生医学盘中异动 股价大跌5.33%报0.355港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610574981","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610574981?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:17","pubTimestamp":1770779852,"startTime":"0","endTime":"0","summary":"2026年02月11日早盘11时17分，中国再生医学股票出现异动，股价快速下跌5.33%。截至发稿，该股报0.355港元/股，成交量22万股，换手率0.07%，振幅8.00%。资金方面，该股资金流入2.765万港元，流出5.5万港元。中国再生医学股票所在的医疗及医学美容服务行业中，整体涨幅为0.35%。中国再生医学公司简介：本公司为投资控股公司,其附属公司的主要业务为提供医美服务及保健产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211111733a6ed05d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211111733a6ed05d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08158","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168229059","title":"中国再生医学国际（08158）1月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1168229059","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168229059?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:02","pubTimestamp":1770022958,"startTime":"0","endTime":"0","summary":"中国再生医学国际有限公司于2026年2月2日发布截至2026年1月31日的证券变动月报表。公告显示，公司本月未进行新增发行、购回或注销活动，股本总数维持不变。报告期末已发行股份仍为304,252,480股，无库存股。本月无任何股份类型出现增减变动。关于股权激励计划，公司披露现行股份期权计划下可发行或转让的潜在股份数量共计30,425,248股，但于1月期间并未有行使或新增授予，亦无股份因此实际发行。本月未发生任何购回或注销股份的情况。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607901584","title":"中国再生医学股价飙升14.29% 市值涨1913万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607901584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607901584?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:12","pubTimestamp":1769739163,"startTime":"0","endTime":"0","summary":"2026年01月30日早盘10时12分，中国再生医学股票出现波动，股价急速拉升14.29%。中国再生医学股票所在的医疗及医学美容服务行业中，整体跌幅为0.31%。其相关个股中，中国再生医学、万嘉集团、康健国际医疗涨幅较大，振幅较大的相关个股有佰泽医疗、脑动极光-B、麦迪卫康，振幅分别为9.89%、7.49%、4.93%。中国再生医学公司简介：本公司为投资控股公司,其附属公司的主要业务为提供医美服务及保健产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026013010124397a41281&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026013010124397a41281&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603956151","title":"中国再生医学盘中异动 快速下跌6.82%报0.410港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603956151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603956151?lang=zh_cn&edition=full","pubTime":"2026-01-16 11:22","pubTimestamp":1768533746,"startTime":"0","endTime":"0","summary":"2026年01月16日早盘11时22分，中国再生医学股票出现异动，股价大幅跳水6.82%。截至发稿，该股报0.410港元/股，成交量5000股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出2050港元。中国再生医学股票所在的医疗及医学美容服务行业中，整体涨幅为0.00%。其相关个股中，瑞慈医疗、万嘉集团、中国生物科技服务涨幅较大，振幅较大的相关个股有天元医疗、中国生物科技服务、瑞慈医疗，振幅分别为12.35%、11.27%、8.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116112226a721119c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116112226a721119c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08158","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603525165","title":"中国再生医学盘中异动 股价大涨7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603525165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603525165?lang=zh_cn&edition=full","pubTime":"2026-01-12 10:07","pubTimestamp":1768183668,"startTime":"0","endTime":"0","summary":"2026年01月12日早盘10时07分，中国再生医学股票出现波动，股价大幅上涨7.23%。截至发稿，该股报0.445港元/股，成交量5000股，换手率0.00%，振幅0.00%。中国再生医学股票所在的医疗及医学美容服务行业中，整体涨幅为0.61%。其相关个股中，一脉阳光、医渡科技、REPUBLIC HC涨幅较大，振幅较大的相关个股有一脉阳光、医脉通、讯飞医疗科技，振幅分别为12.16%、11.21%、10.15%。中国再生医学公司简介：本公司为投资控股公司,其附属公司的主要业务为提供医美服务及保健产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112100748a4b8907a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112100748a4b8907a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crmi.hk","stockEarnings":[{"period":"1week","weight":0.0667},{"period":"1month","weight":-0.1233},{"period":"3month","weight":0.3223},{"period":"6month","weight":-0.3725},{"period":"1year","weight":-0.2809},{"period":"ytd","weight":-0.2381}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国再生医学国际有限公司是一家主要从事提供大健康产品及服务的投资控股公司。该公司从事提供并销售医疗产品及医疗仪器。此外，该公司提供健康状况评估、排毒疗程、体内平衡、养护器官及增强免疫系统等多种健康管理等服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.24,"avgChangeRate":-0.049446},{"month":2,"riseRate":0.6,"avgChangeRate":0.22676},{"month":3,"riseRate":0.36,"avgChangeRate":-0.019341},{"month":4,"riseRate":0.56,"avgChangeRate":0.136675},{"month":5,"riseRate":0.32,"avgChangeRate":-0.037505},{"month":6,"riseRate":0.32,"avgChangeRate":-0.05308},{"month":7,"riseRate":0.25,"avgChangeRate":0.026047},{"month":8,"riseRate":0.24,"avgChangeRate":-0.029035},{"month":9,"riseRate":0.28,"avgChangeRate":-0.109218},{"month":10,"riseRate":0.52,"avgChangeRate":0.115499},{"month":11,"riseRate":0.48,"avgChangeRate":0.113058},{"month":12,"riseRate":0.36,"avgChangeRate":-0.031515}],"exchange":"SEHK","name":"中国再生医学","nameEN":"CRMI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国再生医学(08158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国再生医学(08158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国再生医学,08158,中国再生医学股票,中国再生医学股票老虎,中国再生医学股票老虎国际,中国再生医学行情,中国再生医学股票行情,中国再生医学股价,中国再生医学股市,中国再生医学股票价格,中国再生医学股票交易,中国再生医学股票购买,中国再生医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国再生医学(08158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国再生医学(08158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}